Advertisement

Breast Cancer Trials of the Ludwig and International Breast Cancer Study Group

  • John F. Forbes
  • Richard Gelber
  • Aron Goldhirsch
Part of the Developments in Oncology book series (DION, volume 51)

Abstract

In early 1977 a meeting was convened by the Ludwig Institute for Cancer Research in Switzerland to plan international participation in adjuvant breast cancer trials. The group of international participants have now completed an initial series of four trials (studies I–IV) from July 1, 1978, to August 31, 1981 [1–7]. A fifth trial (study V) involving perioperative therapy completed accrual of 2,517 patients in December 1985 and will be analyzed initially in late 1986. The initial participants group conducting the trials, the Ludwig Breast Cancer Study Group, has now been renamed the International Breast Cancer Study Group (IBCSG), and this group has planned two new adjuvant protocols for commencement during 1986 (studies VI and VII).

Keywords

Breast Cancer Postmenopausal Patient Operable Breast Cancer Adjuvant Systemic Therapy Premenopausal Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ludwig Breast Cancer Study Group. (1985) Adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in 1 to 3 axillary lymph nodes: a randomized trial. Cancer Res. 45:4454–4459.Google Scholar
  2. 2.
    Ludwig Breast Cancer Study Group. (1984) Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet i: 1256–1260.Google Scholar
  3. 3.
    Goldhirsch, A., for the Ludwig Breast Cancer Study Group. (1984) Adjuvant therapy for postmenopausal women with operable breast cancer. Part 1. A randomized trial of chemo-endocrine vs. endocrine therapy vs. mastectomy alone. In Adjuvant Therapy of Cancer IV S.E. Jones and S.E. Salmon (eds.). Orlando: Grune and Stratton, pp. 379–391.Google Scholar
  4. 4.
    Ludwig Breast Cancer Study Group. (1985) Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J. Clin. Oncol. 3:1059–1067.Google Scholar
  5. 5.
    Gelber, R.D., for the Ludwig Breast Cancer Study Group. (1984) Adjuvant therapy for postmenopausal women with operable breast cancer: Part II—Randomized trials comparing endocrine therapy with surgery alone. In Adjuvant Therapy of Cancer IV S.E. Jones and S.E. Salmon (eds.). Orlando: Grune and Stratton, pp. 393–404.Google Scholar
  6. 6.
    Goldhirsch, A., Gelber, R.D., Cavalli, F., Rudenstam, C.-M., Tattersall, M.N.H. and the Ludwig Breast Cancer Study Group. (1985) Adjuvant therapy in postmenopausal node-positive breast cancer. J. of Clin. Oncol. 3:1059–1067.Google Scholar
  7. 7.
    Goldhirsch, A. (1985) Perioperative and conventionally-timed chemotherapy in operable breast cancer. In Perioperative Chemotherapy. Recent Results in Cancer Research U. Metzger, F. Largiader and H.-J. Senn (eds.). Berlin: Springer Verlag, pp. 106–113.Google Scholar
  8. 8.
    Bonadonna, G., Rossi, A., Valagussa, P., Banfi, A. and Veronesi, U. (1977) The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer 39:2904–2915.PubMedCrossRefGoogle Scholar
  9. 9.
    Meakin, J.W., Allt, W.E.C., Beale, F.A., Brown, T.C., Bush, R.S., Clark, R.M., Fitzpat-rick, P.J., Howkins, N.V., Jenkin, R.D.T., Pringle, J.F., Reid, J.G., Rider, W.D., Hay-ward, J.L. and Bulbrook, R.D. (1979) Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Can. Med. Assoc. J. 120:1221–1231.PubMedGoogle Scholar
  10. 10.
    Zava, D.T., Wyler-von Ballmoos, A., Goldhirsch, A., Ross, W., Takahashi, A., Eppenber-ger, U., Arrenbrecht, S., Martz, G., Losa, G., Gomez, F., Guelpa, C. (1982) A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assays. Eur. J. Cancer Clin. Oncol. 18:713–721.PubMedCrossRefGoogle Scholar
  11. 11.
    Bloom, H.J.G. and Richardson, W.W. (1957) Histologic grading and prognosis in breast cancer. Brit. J. Cancer 11:359–377.PubMedCrossRefGoogle Scholar
  12. 12.
    Gelber, R.D. and Zelen, M. (1985) Planning and reporting of clinical trials. In Medical Oncology. Basic Principles and Clinical Management of Cancer P. Calabresi, P.S. Schein and S.A. Rosenberg (eds.). New York: Macmillan, pp. 406–425.Google Scholar
  13. 13.
    Mantel, N., (1966) Evaluation of survival data and two new rank order statisticsarising in its consideration. Cancer. Chemother. Rep. 50:163–170.PubMedGoogle Scholar
  14. 14.
    Cox, D.R. (1972) Regression models and life tables (with discussion). J. Roy. Statist. Soc. (Methodol.) 34:187–220.Google Scholar
  15. 15.
    Gelber, R.D. (1985) Methodological and statistical aspects in perioperative chemotherapy trials. Recent Results in Cancer Research 98:53–63.PubMedGoogle Scholar
  16. 16.
    Forbes, J.F. (1984) The biology of surgery and adjuvant therapy. In Adjuvant Therapy of Cancer IVS.E. Jones and S.E. Salmon (eds.). New York: Grune and Stratton Inc.,pp. 47–60.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • John F. Forbes
  • Richard Gelber
  • Aron Goldhirsch

There are no affiliations available

Personalised recommendations